Press releaseGlobe Newswire
Trevi Therapeutics
TRVI · NASDAQ
$12.83+$0.93 (+7.82%)TodayMarket closed ·
Prev close $11.90
Latest news
- News
Trevi Therapeutics Q2 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
Trevi Therapeutics to Participate in Upcoming September Conferences
- Press releaseGlobe Newswire
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
- Press releaseGlobe Newswire
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Press releaseGlobe Newswire
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
- Press releaseGlobe Newswire
Trevi Therapeutics to Participate in Upcoming August Conferences
- NewsAvi Kapoor
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
- Press releaseGlobe Newswire
Trevi Therapeutics Announces Upcoming June and July Event Schedule
- News
Trevi Therapeutics Q1 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
- News
Earnings Scheduled For May 5, 2026
- Press releaseGlobe Newswire
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
- Press releaseGlobe Newswire
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
- NewsAlex Perry
What's Going On With Trevi Therapeutics Stock?
- Press releaseGlobe Newswire
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
- News
Earnings Scheduled For March 17, 2026
- Press releaseGlobe Newswire
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
- Press releasePRNewswire
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
- Press releasePRNewswire
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
- Press releasePRNewswire
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
- Press releasePRNewswire
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
- News
Earnings Scheduled For November 13, 2025
- News
A Peek at Trevi Therapeutics's Future Earnings
- Press releasePRNewswire
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
- Press releasePRNewswire
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
- Press releasePRNewswire
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
- Press releasePRNewswire
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
- Press releasePRNewswire
Trevi Therapeutics to Participate in Upcoming September Conferences
- Press releasePRNewswire
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
- News
Earnings Scheduled For August 7, 2025
- Press releasePRNewswire
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
- Press releasePRNewswire
Trevi Therapeutics to Participate in Upcoming August Conferences
- Press releasePRNewswire
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
- Press releasePRNewswire
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Press releasePRNewswire
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
- NewsAvi Kapoor
Dow Gains Over 100 Points; US Job Openings Increase In April
- Press releasePRNewswire
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
- Press releasePRNewswire
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
- Press releasePRNewswire
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
- Press releasePRNewswire
Trevi Therapeutics to Participate in Upcoming June Conferences
- News
Earnings Scheduled For May 8, 2025
- News
Earnings Preview For Trevi Therapeutics
- News
Market-Moving News for March 10th
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.